Current stock page

Catalysts

TMDX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareMedical - DevicesScore data as of Sep 4, 2026

TMDX

Catalysts
TransMedics Group, Inc.
Healthcare· Medical - Devices
AIQ Score
NeutralAIQ Edge 4/10
Low Priority
In Line With Peers
Score data as of Sep 4, 2026
Last price
$89.98
+$3.00 (+3.45%)
Latest market quote
Momentum54
Value32
Quality64
Risk Resilience33
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 4, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 47/100

Momentum 54/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 18.86%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 54/100AIQ Edge 4/10 In Line With Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
+26.9%
Across covered historical reports
Latest result
-11.2%
Aug 4, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 4, 2026$0.50$0.44-11.2%$184M$189.95M
May 5, 2026$0.62$0.30-51.6%$174.44M$173.93M
Feb 24, 2026$0.41$0.57+39.0%$155.39M$160.76M
Oct 29, 2025$0.37$0.66+78.4%$155.41M$143.82M
Jul 30, 2025$0.48$0.92+91.7%$141.62M$157.37M
May 8, 2025$0.29$0.70+141.4%$123.39M$143.54M
Feb 27, 2025$0.22$0.19-13.6%$109.49M$121.62M
Oct 28, 2024$0.29$0.12-58.6%$112.18M$108.76M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
8
Buy
4
Hold
12-month analyst target
$101.85
+13.19% versus current price
Based on 7 analyst observations. Targets are estimates, not predictions.
Low target
$65.00
-27.76% vs latest price
Average target
$101.85
+13.19% vs latest price
High target
$142.00
+57.81% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 4, 2026

Next known earnings or reporting date.

EPS estimate$0.27

Current analyst expectation for the upcoming report.

Revenue estimate$177.03M

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score54

Where event reaction would show up first.

AIQ score47/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
7
Average target
$101.85
Target upside
13.19%
Target range
$65.00 - $142.00
90-day revisions
-18

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
gurufocus.com · Sep 4, 2026

TransMedics Group Inc (TMDX) Shares Surge 3.2% -- What GF Score of 69 Tells Investors

On September 03, 2026, TransMedics Group Inc (TMDX) shares rose 3.2% to a current price of $86.98, which is situated within a 52-week range of $60.11 to $156.00

gurufocus.com · Aug 31, 2026

Is TransMedics Group Inc (TMDX) a Bargain After 4.0% Drop? GF Value Says Undervalued

On August 31, 2026, TransMedics Group Inc (TMDX) shares experienced a decline of 4.0%, bringing the current price to $84.87. Over the past 52 weeks, the stock h

seekingalpha.com · Aug 12, 2026

TransMedics Group, Inc. (TMDX) Presents at Canaccord Genuity's 46th Annual Growth Conference - Slideshow (NASDAQ:TMDX) 2026-08-11

2026-08-11. The following slide deck was published by TransMedics Group, Inc.

seekingalpha.com · Aug 6, 2026

TransMedics Stock: Margins Down, Concentration Up, Trials Delayed (NASDAQ:TMDX)

TransMedics' Q2 beat driven by low-margin logistics/pricing, liver concentration risk, delayed ENHANCE/DENOVO catalysts, and rich 45x valuation. See more on TMDX.

seekingalpha.com · Aug 5, 2026

TransMedics Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TMDX) 2026-08-05

2026-08-05. The following slide deck was published by TransMedics Group, Inc.

Open full news and sentiment

TMDX Catalysts FAQ

What are the next catalysts for TMDX stock?

TMDX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TMDX stock?

Upcoming events that could move TMDX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TMDX's next earnings report affect the stock?

TMDX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TMDX stock higher?

TMDX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TMDX stock?

TMDX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.